- Home
- TRS vs ZYME Comparison
TRS vs ZYME Comparison
Compare TRS & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRS
- ZYME
- Stock Information
- Founded
- TRS 1986
- ZYME 2003
- Country
- TRS United States
- ZYME United States
- Employees
- TRS N/A
- ZYME N/A
- Industry
- TRS Industrial Specialties
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- TRS Industrials
- ZYME Health Care
- Exchange
- TRS Nasdaq
- ZYME Nasdaq
- Market Cap
- TRS 1.0B
- ZYME 968.5M
- IPO Year
- TRS 2007
- ZYME 2017
- Fundamental
- Price
- TRS $34.92
- ZYME $12.57
- Analyst Decision
- TRS Strong Buy
- ZYME Buy
- Analyst Count
- TRS 1
- ZYME 7
- Target Price
- TRS $45.00
- ZYME $19.50
- AVG Volume (30 Days)
- TRS 414.6K
- ZYME 410.1K
- Earning Date
- TRS 07-29-2025
- ZYME 08-07-2025
- Dividend Yield
- TRS 0.45%
- ZYME N/A
- EPS Growth
- TRS N/A
- ZYME N/A
- EPS
- TRS 0.91
- ZYME N/A
- Revenue
- TRS $973,840,000.00
- ZYME $93,384,000.00
- Revenue This Year
- TRS $6.37
- ZYME $44.71
- Revenue Next Year
- TRS $5.49
- ZYME $34.57
- P/E Ratio
- TRS $39.29
- ZYME N/A
- Revenue Growth
- TRS 6.72
- ZYME 85.05
- 52 Week Low
- TRS $19.33
- ZYME $9.03
- 52 Week High
- TRS $36.77
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- TRS 78.08
- ZYME 40.67
- Support Level
- TRS $29.93
- ZYME $13.32
- Resistance Level
- TRS $36.77
- ZYME $13.80
- Average True Range (ATR)
- TRS 1.05
- ZYME 0.62
- MACD
- TRS 0.42
- ZYME -0.20
- Stochastic Oscillator
- TRS 75.97
- ZYME 11.28
About TRS TriMas Corporation
TriMas Corp designs, develops and manufactures a diverse set of products primarily for the consumer products, aerospace & defense, and industrial markets . The company operates through three segments namely: The packaging segment manufactures and distributes closure and dispensing systems. The aerospace segment supplies blind bolts, fasteners, rivets, and other products for the aerospace industry. The specialty product segment manufactures and distributes steel cylinders, wellhead engines, compression systems, industrial sealing, and fasteners.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.